Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL 32224, USA.
Parkinsonism Relat Disord. 2020 Dec;81:200-204. doi: 10.1016/j.parkreldis.2020.10.040. Epub 2020 Oct 29.
Multiple system atrophy (MSA) is a rare, sporadic, and progressive neurodegenerative disease which is characterized neuropathologically by alpha-synuclein aggregates in oligodendroglia, and clinically by parkinsonism, ataxia, and autonomic dysfunction. Mitochondrial health influences neurodegeneration and defects in mitochondria, particularly in oxidative phosphorylation, are reported in MSA. Mitochondrial DNA (mtDNA) codes for 13 critical OXPHOS proteins, however no study has investigated if mtDNA variation, in the form of mitochondrial haplogroups, influences MSA risk. Therefore, in this study we investigated the association of mtDNA haplogroups with MSA risk in a case-control manner.
176 pathologically confirmed MSA cases and 910 neurologically healthy controls from Mayo Clinic Jacksonville were genotyped for 39 unique mtDNA variants using Agena Biosciences MassARRAY iPlex technology. Mitochondrial haplogroups were assigned to mitochondrial phylogeny, and logistic regression models that were adjusted for age and sex were used to assess associations between mitochondrial haplogroups and risk of MSA.
After adjusting for multiple testing (P<0.0019 considered significant), no mitochondrial haplogroups were significantly associated with MSA risk. However, several nominally significant (P<0.05) associations were observed; haplogroup I was associated with a decreased risk of MSA (OR=0.09, P=0.021), while an increased risk of MSA was observed for haplogroups H3 (OR=2.43, P=0.017) and T1 and T2 (OR=2.04, P=0.007).
This study investigated whether population-specific mtDNA variation is associated with risk of MSA, and our nominally significant findings suggest mitochondrial haplogroup background may influence MSA risk. Validation of these findings and additional meta-analytic studies will be important.
多系统萎缩症(MSA)是一种罕见的、散发性的、进行性的神经退行性疾病,其病理特征为少突胶质细胞中α-突触核蛋白聚集,临床特征为帕金森病、共济失调和自主神经功能障碍。线粒体健康影响神经退行性变,并且在 MSA 中报道了线粒体的缺陷,特别是在线粒体氧化磷酸化中。线粒体 DNA(mtDNA)编码 13 种关键的 OXPHOS 蛋白,但是没有研究调查过线粒体单倍群形式的 mtDNA 变异是否会影响 MSA 的风险。因此,在这项研究中,我们以病例对照的方式研究了 mtDNA 单倍群与 MSA 风险的关联。
使用 Agena Biosciences MassARRAY iPlex 技术,对来自 Mayo Clinic Jacksonville 的 176 例经病理证实的 MSA 病例和 910 名神经健康对照者进行了 39 种独特的 mtDNA 变异的基因分型。根据线粒体系统发育分配线粒体单倍群,并使用调整了年龄和性别的逻辑回归模型来评估线粒体单倍群与 MSA 风险之间的关联。
在进行多次测试校正后(P<0.0019 认为具有统计学意义),没有线粒体单倍群与 MSA 风险显著相关。然而,观察到了一些名义上显著的(P<0.05)关联;单倍群 I 与 MSA 风险降低相关(OR=0.09,P=0.021),而单倍群 H3(OR=2.43,P=0.017)和 T1 和 T2 与 MSA 风险增加相关(OR=2.04,P=0.007)。
本研究调查了特定人群的 mtDNA 变异是否与 MSA 风险相关,我们的名义上显著的发现表明线粒体单倍群背景可能影响 MSA 风险。这些发现的验证和额外的荟萃分析研究将非常重要。